MilliporeSigma’s New Microbial Bioburden Testing System Offers Enhanced Results and Increased Productivity
The company’s new Milliflex Oasis System provides enhanced result reliability, increased productivity, and advanced traceability.
MilliporeSigma’s latest innovation, the Milliflex Oasis System, offers enhanced benefits for pharmaceutical bioburden and water testing. It has 96 new features to increase result reliability and traceability while streamlining the bioburden testing workflow, the company reports.
The benefits of the new system include:
- Operator-independent handling steps, improved touch-free membrane transfer with color-coded components for increased result reliability
- 50% faster filtration time compared with previous product generation
- Scalable hardware for high throughput
- Reduced decontamination and maintenance time for optimized productivity
- 2-dimensional codes and labels on primary and secondary packaging, on each funnel and media plate, for traceability and regulation compliance
The system also offers an all-in-one filtration solution with sterilized, ready-to-use filtration units and pharmacopeia-compliant media for comfort and peace of mind for water and bioburden testing, according to the company. MilliporeSigma launched the Milliflex Oasis System on Jan. 29, 2020.
Source: MilliporeSigma
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
